Keymed Biosciences, Inc. (HK:2162) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Keymed Biosciences Inc. has announced the approval of their new drug, Stapokibart, by China’s National Medical Products Administration for treating moderate-to-severe atopic dermatitis in adults. This first domestically manufactured IL-4R α antibody drug showed promising results in Phase III clinical trials, meeting primary endpoints and exhibiting a good safety profile. However, the company cautions shareholders that there’s no guarantee of successful commercialization.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.